Health Highlights: Sept. 1, 2016

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

HUD Proposes Lower Lead Level Limits for Children

The U.S. federal housing agency wants to lower the point at which levels of lead in children’s blood would prompt a clean-up of their homes.

Under a proposal announced Wednesday, the level that triggers action would be reduced from 20 to 5 micrograms per deciliter of blood, the Associated Press reported.

The proposal would cover subsidized and public housing, the news service said.

The change would “allow us to act more quickly to make certain the homes we support are as safe as possible. The rule would also require a full environmental investigation rather than just a basic lead assessment, allowing us to more effectively locate and remediate the source of lead exposure,” said U.S. Department of Housing and Urban Development Secretary Julian Castro.

The change would bring HUD lead limits in line with recommendations made in 2012 by the Centers for Disease Control and Prevention, the AP reported.

There is a 60-day public comment period for the proposal, which could affect about 2.9 million subsidized and public housing units built before the United States banned residential lead paint in 1978.

—–

New Drug Shows Promise Against Alzheimer’s

An experimental drug called aducanumab shows promise in treating Alzheimer’s disease, researchers report.

A small clinical trial showed that it significantly reduced toxic plaques in the brains of 165 patients with early-stage Alzheimer’s disease, National Public Radio reported Wednesday.

The findings, published in the journal Nature, suggest the drug may slow the loss of memory and thinking in Alzheimer’s patients.

“If that hint of a clinical benefit is confirmed, it would be a game changer in the fight against Alzheimer’s disease,” said Dr. Eric Reiman, executive director of the Banner Alzheimer’s Institute in Phoenix, NPR reported.

He wrote a commentary that accompanied the study. Much larger clinical trials are needed to confirm whether the drug actually slows Alzheimer’s disease, Reiman said.

Two much larger studies of aducanumab have already been started by drug maker Biogen Inc. Those trials will include 2,700 patients, with results not expected for several years, NPR reported.

—–

New U.S. Funding to Fight Opioid Abuse

The White House is distributing $53 million to 44 states to fight abuse of powerful opioid painkillers.

The money will be used to reduce over-prescribing of the drugs, increase access to treatment, and to make the antidote naloxone widely available, said Health and Human Services Secretary Sylvia Burwell, the Associated Press reported.

The Obama administration also wants Congress to provide $1.1 billion in new money to tackle the problem. Recently approved $181 million in new spending did not do enough to expand treatment, the White House said.

New federal funding is urgently needed so that people who require treatment don’t have to wait months, Steve Williams, the mayor of Huntington, West Virginia, said in a conference call announcing the funding, the AP reported.

Williams said opioid abuse in his community is so common that he carries an overdose reversal kit with him.